The global gene therapy market is segmented by regions into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa. At the global level, the market is predicted to grow on the back of growing healthcare expenditure along with an increasing demand for improved treatment practices all over the world. As per the World Bank, the global current healthcare expenditure (% GDP) was estimated to rise from 9.453% in 2011 to 10.023% in 2016.

The gene therapy market in North America is estimated to observe a significantly high growth on account of rising incidences of diseases such as cardiovascular disease in the region which is driving the demand for effective prevention and treatment methods. In 2018, the American Heart Association reported that around 2,300 Americans die from cardiovascular disease every day. The market in the United States is anticipated to grow exponentially as a result of growing research and development activities in the region along with the expanding applications of gene therapy. Gene therapy market in Europe is estimated to expand substantially on account of growing healthcare expenditure in the region, mainly in countries such as Germany. This can be attributed to the increasing cases of disorders in the region which raises the demand for application of modern technologies in hospitals.  CLICK TO DOWNLOAD SAMPLE REPORT

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).